Veradigm (MDRX) Competitors

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Which has more volatility and risk, OMCL or MDRX?

Omnicell has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Veradigm has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Is OMCL or MDRX more profitable?

Omnicell has a net margin of 1.87% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.60% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.87%	4.60%	2.56%
Veradigm	N/A	N/A	N/A

Does the media prefer OMCL or MDRX?

In the previous week, Veradigm had 2 more articles in the media than Omnicell. MarketBeat recorded 3 mentions for Veradigm and 1 mentions for Omnicell. Omnicell's average media sentiment score of 1.14 beat Veradigm's score of 1.11 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of OMCL or MDRX?

97.7% of Omnicell shares are owned by institutional investors. 2.5% of Omnicell shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts rate OMCL or MDRX?

Omnicell presently has a consensus price target of $44.83, suggesting a potential upside of 51.67%. Veradigm has a consensus price target of $13.00, suggesting a potential upside of 168.04%. Given Veradigm's higher possible upside, analysts plainly believe Veradigm is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Veradigm	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has stronger earnings and valuation, OMCL or MDRX?

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.11B	1.24	$12.53M	$0.46	64.26
Veradigm	$1.53B	0.34	N/A	N/A	N/A

Summary

Omnicell beats Veradigm on 9 of the 13 factors compared between the two stocks.